Menopause Myth: “Hormone therapy causes cancer.”

Menopause Myth: “Hormone therapy causes cancer.”

If you’ve ever heard “Don’t take hormones—you’ll get cancer,” you’re not alone. That fear traces back to early headlines from the Women’s Health Initiative (WHI) in the early 2000s. The problem is: those headlines got simplified into a scary soundbite that doesn’t reflect what we know now.

The truth is more nuanced (and much more reassuring): menopausal hormone therapy (MHT) affects cancer risk differently depending on the type of hormone used, whether you still have a uterus, your personal risk factors, and how long you use it. (Cancer.gov)

Let’s break it down in plain English.

First, what “hormone therapy” actually means

When people say “hormone therapy,” they’re usually referring to systemic estrogen (to treat hot flashes/night sweats) with or without a progestogen (progesterone-like medication).

• If you have a uterus: you generally need estrogen + progestogen to protect the uterine lining.
• If you do NOT have a uterus (hysterectomy): you can often use estrogen-only therapy.

That distinction matters a lot for cancer risk.

Breast cancer: what the data actually shows

1) Combined estrogen + progestin: a small increase with longer use

The WHI trial of estrogen + progestin found an absolute increase of ~8 additional invasive breast cancers per 10,000 women per year compared with placebo. (Kaiser Permanente Division of Research)

Why the WHI headlines didn’t age well (and what they left out)

Most of the fear around menopausal hormone therapy (MHT) traces back to early 2000s headlines from the Women’s Health Initiative (WHI). Those headlines were loud—“hormones cause cancer,” “hormones are dangerous”—and they stuck. But over time, clinicians and researchers recognized important flaws in how those results were interpreted for the average woman seeking menopause symptom relief today.

Here’s what often gets missed:

• WHI studied a different population than most women who start MHT now.
  Many participants were older (average age ~63) and a large number were 10+ years past menopause. That matters because hormone therapy started later in life can behave very differently than therapy started around the menopause transition.
• It wasn’t “typical” modern hormone therapy.
  WHI primarily used one specific formulation and dose (oral conjugated equine estrogen, with medroxyprogesterone acetate in the combined arm). Today, many women use different options (including lower doses, and in some cases transdermal estrogen and micronized progesterone), which may have different risk profiles.
• The message got oversimplified into a scary soundbite.
  The WHI findings were reported as relative risk increases, but the absolute risk changes for most outcomes were small—and that nuance rarely made it into the public conversation.
• Two arms, two different stories.
  WHI results differed substantially between estrogen-only therapy (for women without a uterus) and estrogen + progestin (for women with a uterus). The public takeaway blurred these together into one blanket “hormones are bad” message.

Bottom line: WHI was a valuable study, but it was not a perfect match for the typical woman today who is 45–55, symptomatic, and seeking relief close to the menopause transition. The best decision comes from your personal risk factors, your symptoms, and choosing the right formulation, route, and dose—not from a one-size-fits-all headline.

Also important: combined therapy can increase breast density, which can make mammograms harder to interpret and may contribute to delayed detection. (Cancer.gov)

2) Estrogen-only therapy: no increased breast cancer risk in WHI—and may be lower

In the WHI estrogen-only arm (used in women without a uterus), systemic estrogen was associated with a lower risk of breast cancer in follow-up analyses. The National Cancer Institute summarizes this as “lower risk of breast cancer” and “lower risk of death from breast cancer” with systemic estrogen in that population. (Cancer.gov)

3) Short-term use: breast cancer risk doesn’t “jump overnight”

A key point many women never hear: short-term use of hormone therapy—especially for symptom relief around the menopause transition—does not carry the same risk profile as long-term use.

The Menopause Society (formerly NAMS) highlights that breast cancer risk does not increase appreciably with short-term use of estrogen-progestogen therapy and may be decreased with estrogen alone. (letstalkmenopause.org)
The American Cancer Society similarly notes that short-term estrogen-progestin therapy is not thought to increase breast cancer risk (risk becomes more relevant with longer duration). (American Cancer Society)

Uterine (endometrial) cancer: the “unopposed estrogen” issue

Here’s the clearest cancer takeaway in menopause care:

• Estrogen-only therapy in someone with a uterus increases endometrial cancer risk if the uterine lining isn’t protected. (Cancer.gov)
• Adding a progestogen dramatically reduces that risk by counteracting estrogen’s effect on the endometrium (uterine lining).

This is why an individualized plan matters: the goal is to treat symptoms while protecting the uterus appropriately.

What about ovarian cancer, colon cancer, and other cancers?

Cancer risk signals outside breast and endometrial cancer exist, but they are generally smaller, more variable, and depend on the formulation and duration.

From WHI, estrogen + progestin was associated with fewer colorectal cancers (about 6 fewer cases per 10,000 women per year) in the trial’s primary results. (Kaiser Permanente Division of Research)
But cancer outcomes should never be the only reason to start or avoid therapy—your symptom burden, bone health, cardiovascular timing, clot risk, and personal/family history all matter too. (Cancer.gov)

Ready for a personalized, evidence-based plan?

At Menopause Solutions, LLC, we help women of the Charleston and Mt.Pleasant area make a confident decision using symptom profile, personal/family history, and risk factors—so you’re not stuck choosing between suffering and scary headlines.  our experienced providers, Elaine Eustis, MD, FACOG, MSCP and Rhonda Leach, DNP, WHNP, MSCP are here to help women navigate through menopause and perimenopause

If you’re struggling with hot flashes, poor sleep, mood changes, or “I don’t feel like myself,” schedule a menopause consult with our team. We’ll walk you through your options—including hormone and nonhormone treatments—and tailor a plan that fits your body and goals.